News & Updates

Long-term lecanemab reduces cognitive decline in early AD
Long-term lecanemab reduces cognitive decline in early AD
30 Apr 2024 byStephen Padilla

Treatment with lecanemab continue to provide benefits to patients with early Alzheimer’s disease (AD) through 24 months, according to the results of the ongoing open-label extension study of Clarity AD. Those who have been treated much later also show disease improvements.

Long-term lecanemab reduces cognitive decline in early AD
30 Apr 2024
Does BMI affect functional outcomes in stroke patients on rehab?
Does BMI affect functional outcomes in stroke patients on rehab?
30 Apr 2024 byStephen Padilla

A study in Singapore provides further evidence regarding the benefits of poststroke rehabilitation in improving function, reducing disability, and discharging patients. In addition, the results show that body mass index (BMI) in any category does not predict the ability to attain functional independence following inpatient rehabilitation.

Does BMI affect functional outcomes in stroke patients on rehab?
30 Apr 2024
Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
30 Apr 2024 byMike Ng

Treating COVID-19 patients who had been vaccinated or did not have risk factors for severe disease with ritonavir-boosted nirmatrelvir (nirmatrelvir–ritonavir) did not expedite the time to symptom alleviation, reported investigators in the EPIC-SR trial.

Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
30 Apr 2024